Candel Therapeutics Inc (NASDAQ:CADL) will deliver three presentations at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
“Candel’s presentations at SITC 2025 exemplify our innovative approach to the discovery and development of novel immunotherapies,” said CEO Paul Peter Tak. “By leveraging next-generation research tools we are working to generate deep biological insights that inform every stage of drug development, from bench to bedside and back.”
Tak will deliver an invited presentation and join a panel discussion on November 7, highlighting positive phase 3 data for CAN-2409 in newly diagnosed, localized prostate cancer. The company plans to submit a Biologics License Application (BLA) for the therapy in the fourth quarter of 2026.
In another presentation, Daniel Sterman, MD of NYU Langone Health, will present data from a phase 2a trial of CAN-2409 in patients with stage III/IV non-small cell lung cancer (NSCLC) who had progressed despite immune checkpoint inhibitor treatment.
Using multi-omics factor analysis to integrate over 3,000 data points, researchers observed that patients with non-squamous disease showed stronger immune activation and improved survival compared to those with squamous histology.
“The enhanced immune activation and improved survival observed after CAN-2409 administration in patients with non-squamous disease support the rationale for a phase 3 clinical trial in this subgroup,” Sterman said.
Candel will also present preclinical data from its AI-driven enLIGHTEN Discovery Platform. Dr Anne Diers, vice president of research, will discuss a new candidate, Alpha-201, engineered to express IL-12 and IL-15 for the treatment of breast cancer.
The therapy demonstrated tumor growth suppression in animal models and triggered immune responses involving T cells, natural killer cells, and dendritic cells.